Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• semaglutide — DRUG
  Once weekly, administrated subcutaneously (s.c. under the skin)
• placebo — DRUG
  Once weekly, administrated subcutaneously (s.c. under the skin)

Study Details

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).

Key Dates

Start date

Feb 3, 2014

Status verified

May 2019

Primary completion

May 8, 2015

Completion

May 8, 2015

Study Design

Enrollment

388 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Semaglutide 1.0 mg
• Experimental: Semaglutide 0.5 mg
• Placebo Comparator: Semaglutide placebo 1.0 mg
• Placebo Comparator: Semaglutide placebo 0.5 mg

Primary Outcome Measure

Change in HbA1c (Glycosylated Haemoglobin) [ Time Frame: Week 0, week 30 ]

Locations (38)

Find similar trials in Anniston, AL

Related Studies

• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
  PHASE1/PHASE2 · Recruiting · Midhat H. Abdulreda · Miami, Florida
• Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
  Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
• Blood Markers of Early Pancreas Cancer
  Recruiting · University of Nebraska · Omaha, Nebraska